Teva GmbH

DUBLIN--( BUSINESS WIRE )--The "United States Connected Drug Delivery Devices Market by Product Type, Technology, Application, End-user, Region, Competition Forecast & Opportunities, 2028F" report has been added to ResearchAndMarkets.com's offering. The United States connected drug delivery devices market is expected to register an impressive growth rate to 2028 The market showed consistent growth in the historical years from 2018-2022 on account of an increase in awareness among consumers regarding the use of self-administrated and connected drug therapy. The rise in the cost of in-patient stays at healthcare facilities, along with the high demand for advanced drug delivery solutions, is expected to fuel the market demand. Improvement in the quality of patient care and compliance and the changing healthcare infrastructure is expected to boost the United States connected drug delivery devices market growth. Connected sensors have convenient integration with the existing delivery devices, and thus they dominate the market. The segment is anticipated to dominate the United States connected drug delivery devices market in the next five years. Connected sensors do not interfere with the working of delivery devices and are reusable even if the delivery device is disposed of. Moreover, increasing cases of chronic respiratory diseases and chronic obtrusive pulmonary disease are expected to boost the demand for integrated connected drug delivery devices in the future. The smart wireless electronic systems developed for the delivery of the desired drug, commonly known as connected drug delivery devices, result in patient monitoring and counseling the patients with conditions such as asthma, diabetes, hepatitis C, hypertension, tuberculosis, Chronic Obstructive Pulmonary Diseases (COPD), etc. Additionally, the rise in initiatives and campaigns by healthcare facilities and top authorities to promote the benefits of taking prescribed drugs at the right time and on time to ensure that patients receive effective treatment is anticipated to support the growth of the connected drug delivery devices market. Also, the awareness regarding the benefits of connected systems over the traditional drug delivery system with improved patient response is expected to accelerate the growth of the United States connected drug delivery devices market. Rise in Prevalence of Chronic Diseases Connected drug delivery systems support doctors in keeping track of their patients in determining the effectiveness of prescribed treatments and adjusting the patient's care as required. For instance, for people with chronic diseases such as diabetes and asthma, connected drug-delivery devices can be helpful for self-medication management. According to the Asthma and Allergy Foundation of America, in the United States, about 20 million adults below and above the age of 18 years have asthma; around 9.8% of female adults have asthma, compared to 6.1% of male adults. These factors are anticipated to boost the growth of the United States connected drug delivery devices market in the forecast years. Increasing R&D Activities Rapid advancements in research and development (R&D) for developing drug-delivering devices for the treatment of infectious/chronic diseases are contributing to market growth. For instance, according to several researchers, the United States spent USD607.5 billion in R&D activities, with USD101.1 billion (17%) of annual R&D spending classified as basic research. Additionally, a pharmaceutical company, namely Eli Lily, in 2021, the cooperation of four distinct businesses - Gloko Inc., DexCom Inc., Roche, and my Diabby Healthcare - works to promote connected solutions for diabetics in international markets, driving the growth of the United States connected drug delivery devices market. Growing Awareness Amongst Patients to Boost Medication Connected drug delivery devices offer the right dosage and administration for successful treatment without any cost-efficient interventions. According to Clinicaltrials.gov, 13 clinical trials took place for the development of connected drug delivery devices. Due to the awareness amongst people, more and more patients are adopting these delivery devices to support treatment more efficiently, thus helping to reduce the number of visits to clinics and hospitals and reduce the patient's efforts to comply with prescribed medication. Additionally, it reduces the wastage of costly medications such as injectable biologics and is expected to fuel the growth of the United States connected drug delivery devices market. Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the United States connected drug delivery devices market. Abbott Laboratories, Inc. F. Hoffmann-La Roche Ltd. (USA) Reciprocal Labs Corporation (Propeller Health) Teva USA Merck & Co. West Pharmaceutical Services, Inc. Molex LLC (Phillips Medisize) Cohero Health, Inc. Becton, Dickinson, and Company Unilife Corporation Report Scope United States Connected Drug Delivery Devices Market, By Product Type: Connected Sensors Integrated Connected Devices United States Connected Drug Delivery Devices Market, By Technology: Bluetooth Near Field Communication Others United States Connected Drug Delivery Devices Market, By Application: Asthma & COPD Diabetes Others United States Connected Drug Delivery Devices Market, By End User: Healthcare Providers Homecare United States Connected Drug Delivery Devices Market, By Region: North-East Mid-West South West For more information about this report visit https://www.researchandmarkets.com/r/xcmfel About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

SAN DIEGO--(BUSINESS WIRE)-- National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that William S. Marth, RPh., MBA has been appointed to the newly created role of President of Services. This press release features multimedia. View the full release here: Bill Marth, President of Services, Resilience (Photo: Business Wire) In this role, Mr. Marth will have end-to-end responsibility for all development and manufacturing services and commercial activities at Resilience. Resilience’s objective in creating the new Services organization is to strengthen the company’s focus on providing the highest quality execution for pre-clinical, clinical and commercial programs. “Having worked in the global biopharmaceutical industry for more than thirty years, I know the crucial role that biomanufacturing plays to ensure efficient delivery of important medicines to patients,” said Mr. Marth. “I am thrilled to join the esteemed executive team at Resilience, and I look forward to partnering with the team to deliver on Resilience’s mission.” Prior to joining Resilience, Mr. Marth previously served as a Director (2012) and Chairman of the Board (2013) of AMRI (NASDAQ) (now known as Curia Global, Inc.) before assuming the role of Chief Executive Officer from 2014 through 2018. In 2017, Mr. Marth led the sale of AMRI to Carlyle and GTCR for $1.65 billion. Additionally, he previously served as President and CEO of Teva Pharmaceuticals Industries Ltd. for the Americas and CEO of Teva North America and Teva USA. “Bill has an unparalleled record of corporate success, and we are thrilled to welcome a seasoned life sciences industry leader to our team,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. “We look forward to benefitting from his experience and capability to better serve our customers and further scale Resilience.” About Resilience Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell/ gene therapy modalities and drug product). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.

Pictured: Teva U.S. headquarters in New Jersey/iStock, JHVEPhoto Teva Pharmaceuticals has broadened its existing collaboration with biosimilar-focused Alvotech along with a $40 million purchase of the latter’s subordinated convertible bonds, the companies announced Monday. Though exact details of the expanded agreement remain sparse, Teva will have “increased involvement” regarding manufacturing and quality and control at Alvotech’s Iceland facility, which the partners are currently preparing for another round of FDA inspections, according to the press release. Alvotech is developing AVT02, a biosimilar to AbbVie’s Humira (adalimumab) for the treatment of rheumatoid arthritis, Crohn’s disease and other inflammatory conditions. In April 2023, however, the FDA denied Alvotech’s Biologics License Application (BLA) for AVT02, pointing to “certain deficiencies” at its Reykjavik manufacturing plant that “must be satisfactorily resolved before the application can be approved.” An FDA warning letter following an inspection in March 2023 revealed several issues at Alvotech’s Iceland facility, including “an unacceptably high number of mold recoveries” in rooms designated for drug manufacturing. Bacterial contamination has also exceeded acceptable levels and the company’s corrective and preventive actions for these “were inadequate to avoid future occurrences,” according to the regulator. A second BLA for AVT02, which sought the FDA’s interchangeability designation, was also rejected in June 2023. In its Complete Response Letter, the FDA again cited quality deficiencies at the Reykjavik site. These rejections pushed Teva to take a more hands-on approach to Alvotech’s manufacturing plant, a Teva spokesperson told Endpoints News. AVT02 is part of the companies’ initial partnership, which was signed in August 2020, and covers four other biosimilar candidates—including AVT04, an investigational biosimilar to J&J’s Stelara (ustekinumab), also for inflammatory conditions. Under the terms of Monday’s expanded agreement, Teva will also gain exclusive U.S. commercialization rights to two new biosimilar candidates. The partners have also agreed to line extensions for two current candidates in the original deal. Alvotech will take charge of development and manufacturing, as well as be eligible for milestones such as product approvals. Teva and Alvotech will also share the profits from these biosimilars, though the specific financial details of the expanded deal remain confidential. In other Teva news, the company has settled its patent dispute over Exelixis’ cancer drug Cabometyx (cabozantinib). The California-based biotech filed the lawsuit in 2022, challenging Teva’s abbreviated New Drug Application for its generic candidate. Under the settlement, Exelixis will allow Teva to market its generic version of Cabometyx, pending FDA approval, starting on January 1, 2031. Tristan Manalac is an independent science writer based in metro Manila, Philippines. He can be reached at tristan@tristanmanalac.com or tristan.manalac@biospace.com.